Pharma BD Deal Intelligence
Termeer frames divestiture as sharpening focus on rare disease pipeline; deal is part of broader portfolio response to manufacturing issues and Sanofi's…
Sekisui pays $265M for Genzyme's diagnostics business; Genzyme stock closed up 5 cents at $70.27, reflecting investor approval of the strategic restructuring.
The acquisition will enable Sekisui Medical to build upon this historical relationship and establish an even firmer platform for Sekisui Medical's growth…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Genzyme agreed to sell Diagnostics business to Sekisui Chemical for $265M cash. 2009 revenue $167M with ~575 employees. Closed February 1, 2011.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sekisui Chemical Co., Ltd. / Genzyme Diagnostic Products business (this deal) | 2010 | $265M | 64 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2010 deals · Cardiovascular deals